knowledge -WSS

knowledge

author：hotspot 2025-10-01 14:20:31 - browse：111

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

explore

WSS

Peter Marks talks Operation Warp Speed for Rare Diseases

Man who had jail sentence commuted by Trump arrested again

European regulators consider appeal over Amylyx ALS drug

Celebrate National Dole Whip Day for 3 days this week at Disney

How should state employee insurance handle Wegovy?

Life sciences deals on track to hit lowest point since 2017

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

DOJ, FTC to increase scrutiny of all types of health care mergers

Supreme Court strikes down use of affirmative action

Why some people catch Covid but never get sick

Moonlake's readout produced a cash windfall. Risks remain

Eight reasons why you should get an updated Covid vaccine

Alkermes shareholders re

Cancer cells are shown to suck energy source from immune cells

Guidelines to prevent youth baseball injuries need more muscle

Readout LOUD podcast: Merger Mondays, Ozempic panic

leisure time

Celebrate National Dole Whip Day for 3 days this week at Disney

Stanford updates investigation of president’s past research

How clinical AI models' predictive power can degrade over time

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

STAT Readout: Today's biotech news includes Sana and Amylyx

How doctors and nurses shape Google's AI

explore

hotspot

explore

entertainment